Journal
TRENDS IN MOLECULAR MEDICINE
Volume 22, Issue 1, Pages 53-67Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2015.11.001
Keywords
-
Funding
- US National Institutes of Health [AI075285, AI093903]
- National Multiple Sclerosis Society [RG4111A1, JF2161-A-5]
- International Progressive MS Alliance [PA0069]
- Regional Ministry of Economy, Science and Innovation [P11-CTS-8161]
- Regional Ministry of Health [PI13-575]
- PAIDI Program from the Andalusian Government [CTS-677]
- Spanish Ministry of Economy and Competitiveness
- FEDER [PI14-1600, 2012-39720, CP10-00527]
- CONACyT (Mexico)
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI093903, K99AI075285, R01AI093903, R00AI075285] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease that primarily affects motor neurons and is accompanied by sustained unregulated immune responses, but without clear indications of the ultimate causative mechanisms. The identification of a diverse array of ALS phenotypes, a series of recently discovered mutations, and the links between ALS and frontotemporal degeneration have significantly increased our knowledge of the disease. In this review we discuss the main features involved in ALS pathophysiology in the context of recent advances in 'omics' approaches, including genomics, proteomics, and others. We emphasize the pressing need to combine clinical imaging with various different parameters taken from omics fields to facilitate early, accurate diagnosis and rational drug design in the treatment of ALS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available